Cover Image


Global Breast Cancer Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 306317
出版日期 內容資訊 英文 117 Pages
Back to Top
全球乳癌市場 Global Breast Cancer Market 2014-2018
出版日期: 2014年06月13日 內容資訊: 英文 117 Pages



第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

  • 市場概要
  • 產品概要
    • 產品簡介

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 乳癌的治療計劃

第8章 各治療市場區隔

第9章 各分子市場區隔

第10章 乳癌的全球單株抗體市場

第11章 臨床實驗平台組合

第12章 各地區市場區隔

  • 南北美洲的乳癌藥物市場
    • 市場規模與預測
  • 歐洲、中東、非洲地區的乳癌藥物市場
    • 市場規模與預測
  • 亞太地區乳癌藥物市
    • 市場規模與預測
    • 各國市場區隔

第13章 購買標準

第14章 推動市場成長要素

第15章 推動因素與其影響

第16章 市場課題

第17章 推動因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
    • 最新資訊
    • 合併、收購
  • 市場佔有率分析
    • Hoffmann-La Roche Ltd.
    • Astrazeneca PLC
    • Novartis AG
    • Sanofi-Aventis
    • Eli Lilly and Company
  • 其他值得注意的供應商
  • 預計開拓乳癌市場的未來加入廠商

第21章 主要供應商分析


Product Code: IRTNTR3609

About Breast Cancer

Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.

TechNavio's analysts forecast the Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:

  • HER2-negative breast cancer
  • HER2-positive breast cancer
  • Hormone receptor positive breast cancer
  • Hormone receptor negative breast cancer
  • Advanced breast cancer
  • Early breast cancer
  • Operable node positive breast cancer
  • Metastatic breast cancer
  • Triple Negative Breast Cancer

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Breast Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC
  • Key Vendors
  • Astrazeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi-Aventis

Other Prominent Vendors

  • Accord Healthcare, Inc.
  • Pfizer, Inc.
  • Hospira, Inc.
  • Actavis, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • DARA BioSciences, Inc.
  • Eisai Inc.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hospira, Inc.
  • Immunovative Therapies, Ltd
  • Nektar Therapeutics
  • Nippon Kayaku Co., Ltd
  • Pfizer Inc.
  • Pierre-Fabre Medicament
  • ProStrakan, Inc.
  • Pt Dexa Medica
  • Sorrento Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

Key Market Driver

  • Increase in Breast Cancer Population.

For a full, detailed list, view our report.

Key Market Challenge

  • Poor Diagnosis and Screening.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Treatment Regimen for Breast Cancer

08. Market Segmentation by Type of Therapy

09. Market Segmentation by Molecule Type

10. Global Monoclonal Antibodies Market in Breast Cancer

11. Clinical Pipeline Portfolio

12. Geographical Segmentation

  • 12.1. Breast Cancer Drugs Market in the Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. Breast Cancer Drugs Market in the EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Breast Cancer Drugs Market in the APAC Region
    • 12.3.1. Market Size and Forecast
    • 12.3.2. Country-wise Segmentation of APAC 2013

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
    • 20.2.1. F. Hoffmann-La Roche Ltd.
    • 20.2.2. Astrazeneca PLC
    • 20.2.3. Novartis AG
    • 20.2.4. Sanofi-Aventis
    • 20.2.5. Eli Lilly and Company
  • 20.3. Other Prominent Vendors
  • 20.4. Future Players Expected to Tap the Market

21. Key Vendor Analysis

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Breast Cancer Market 2013-2018 (US$ billion)
  • Exhibit 3: List of Breast Cancer Drugs Served by Other Prominent Players
  • Exhibit 4: Staging of Breast Cancer Based on Tumor Size and Extent of Metastasis
  • Exhibit 5: Classification of Breast Cancer Based on Genetic Make-up of Tumor Cells
  • Exhibit 6: Treatment Regimen for Breast Cancer
  • Exhibit 7: Global Breast Cancer Market Segmentation by Type of Therapy 2013 (Revenue in Percentage)
  • Exhibit 8: Molecule Type For Commonly Used APIs in Breast Cancer
  • Exhibit 9: Global Breast Cancer Drugs Market by Geographical Segmentation 2013
  • Exhibit 10: Pain Management Drugs Market in the Americas 2013-2018 (US$ billion)
  • Exhibit 11: Pain Management Drugs Market in the EMEA Region 2013-2018 (US$ billion)
  • Exhibit 12: Breast Cancer Drugs Market in the APAC Region 2013-2018 (US$ billion)
  • Exhibit 11: Country-wise Segmentation of APAC 2013 (revenue in percent)
  • Exhibit 13: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
  • Exhibit 14: Product Portfolio of Roche's Breast Cancer Products in US
  • Exhibit 15: Geography Wise Segmentation for Roche's Products Used in Breast Cancer (in percent)
  • Exhibit 16: Product Portfolio of Astrazeneca's Breast Cancer Products in US
  • Exhibit 17: Geography Wise Segmentation for Astrazeneca Products Used in Breast Cancer (in percent)
  • Exhibit 18: Product Portfolio of Novartis's Breast Cancer Products in US
  • Exhibit 19: Geography Wise Segmentation for Novartis's Breast Cancer Products (in percent)
Back to Top